August 7, 2024 09:03 AM EDTUpdated 06:19 PM

Inspection delays hold back BeiGene's Tevimbra progress once again

Max Bayer

Pharma Reporter

BeiGene will need to wait a bit longer for an FDA decision on cancer immunotherapy, Tevimbra, citing a delay in scheduling clinical site inspections. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Inspection delays hold back BeiGene's Tevimbra progress once again

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK leaves biotech trade group BIO

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

New Trump era could be a boon for biopharma M&A, dealmaking

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

In­spec­tion de­lays hold back BeiGene's Tevim­bra progress once again

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK leaves biotech trade group BIO

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Is there room for MASH drugs in a GLP-1 world?

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Inspection delays hold back BeiGene's Tevimbra progress once again

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

New Trump era could be a boon for biopharma M&A, dealmaking

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks